PI3K in CLL: Are 2 isoforms better than 1?

Abstract

In this issue of Blood, Dong et al present a series of experiments with the novel B-cell receptor (BCR) kinase inhibitor IPI-145 (phosphatidylinositol 3-kinase γ/δ [PI3Kγ/δ] inhibitor) and show that chronic lymphocytic leukemia (CLL) samples resistant to ibrutinib remain sensitive to killing by this agent.